banner
Epigenetic reader domain inhibitor UNC 669, Purity ≥98%
Inquiry

Cat. No.: X24-05-ZQ483

Epigenetic reader domain inhibitor UNC 669, Purity ≥98%

Inquiry

Synonym: 1314241-44-5; UNC669; UNC-669; Epigenetic reader domain inhibitor

  • CAS Number: 1314241-44-5
  • Compound CID: 46931242
img
Product Size
10 mg; 25 mg; 50 mg; 100 mg
Price
Datasheet
Datasheet
MSDS
MSDS
Properties
Description
UNC 669, soluble in DMSO and ethanol and insoluble in water, disrupts the function of proteins that recognize and bind specific epigenetic marks, affecting the interpretation of epigenetic signals. It targets L3MBTL1, L3MBTL3, and L3MBTL4.
Molecular Weight
338.24
Molecular Formula
C15H20BrN3O
Targets
L3MBTL1: 6 μM; L3MBTL3: 35 μM; L3MBTL4: 69 μM
Form
Lyophilized powder
Purity
≥98%
Solubility
DMSO: 10 mg/mL (29.56 mM); Water: Insoluble; Ethanol: 62 mg/mL (183.3 mM)
Identity
Confirmed by NMR/HPLC/MS.
Applications
UNC 669 is employed in the study of the L3MBTL1 methyl-lysine reader domain and its biological significance.
Publications
Publications (0)

Publications

×
Publications

Thank you for choosing our products for your research. By sharing your publications or experimental feedback, you provide invaluable insights that help fellow scientists accelerate their discoveries. Your contribution also drives our commitment to continuous product optimization.

As a token of our appreciation, verified submissions will receive an exclusive discount code for your next order.

*Submitted research data and images may be featured on our product pages. We strictly protect your personal privacy; no sensitive contact information will ever be disclosed.

  • You can upload up to 5 images or ZIP files, and the size of a single file may not exceed 5MB.
Related Products
Quick Links
(AI-CD BioGlyco)
Analysis of Sialic Acid in Human Milk
(CD BioGlyco)
Biological Evaluation Service
(CD BioGlyco)
Glyconanotechnology-based Biosensor Development
PRODUCTS
Featured Products
Nucleic Acid Drug Delivery Products
GalNAc-L96 intermediate, T1 (Cat#: X24-11-YM010) GalNAc-L96 intermediate, T2 (Cat#: X24-11-YM011) GalNAc-L96 intermediate, T3 (Cat#: X24-11-YM012) GalNAc-L96 intermediate, T4-Amine (Cat#: X24-11-YM014) Tri-GalNAc(OAc)3 Cbz (Cat#: X24-11-YM015) Tri-GalNAc(OAc)3 (Cat#: X24-11-YM016) Tri-GalNAc(OAc)3 TFA (Cat#: X24-11-YM017) GalNAc-L96-OH (Cat#: X24-11-YM018) GalNAc-L96-TEA (Cat#: X24-11-YM019)
Hots Products
N-Glycan
Neu5Gcα(2-6)N-Glycan (Cat#: X23-03-YW036) A2G2 N-Glycan (Cat#: X23-03-YW037) A2G2S2 N-Glycan (Cat#: X23-03-YW038) A2 N-Glycan (Cat#: X23-03-YW039) A2[6]G1 N-Glycan (Cat#: X23-03-YW040) M3 N-Glycan (Cat#: X23-03-YW041) A2[3]G2S1 N-Glycan (Cat#: X23-03-YW042)
O-Glycan
Core 2 O-glycan, Ser-Fmoc linked (Cat#: X23-10-YW178) Core 2 O-glycan, Thr-Fmoc linked (Cat#: X23-10-YW179) Core 3 O-glycan, Ser-Fmoc linked (Cat#: X23-10-YW180) Core 3 O-glycan, Thr-Fmoc linked (Cat#: X23-10-YW181) Core 4 O-glycan, Ser-Fmoc linked (Cat#: X23-10-YW182) T antigen O-glycan, Ser-Fmoc linked (Cat#: X23-10-YW192) T antigen O-glycan, Thr-Fmoc linked (Cat#: X23-10-YW193) Tn antigen O-glycan, Ser-Fmoc linked (Cat#: X23-10-YW194)
Blood Group and Lewis Antigen
Blood group A trisaccharide (Cat#: XCO0060Q) Blood group B trisaccharide (Cat#: XCO0068Q) Blood group H disaccharide (Cat#: XCO0074Q) Lewis A trisaccharide (Cat#: XCO0079Q) 3'-Sulfated lewis A (Cat#: XCO0080Q) Lewis B tetrasaccharide (Cat#: XCO0083Q) Lewis X trisaccharide (Cat#: XCO0085Q) Lewis Y tetrasaccharide (Cat#: XCO0088Q)
Human Milk Oligosaccharides (HMOs)
Lacto-N-biose (Cat#: XCO0089Q) 2'-Fucosyllactose (Cat#: XCO0091Q) 3-Fucosyllactose (Cat#: XCO0092Q) Lactodifucotetraose (Cat#: XCO0093Q) Lacto-N-triose I (Cat#: XCO0094Q) 3'-Sialyllactose sodium salt (Cat#: XCO0096Q) 6'-Sialyllactose sodium salt (Cat#: XCO0098Q) 3'-Sialyl-3-fucosyllactose (Cat#: XCO0100Q)
Glycosaminoglycans
Heparin amine, MW 27 kDa (Cat#: X22-09-ZQ478) FITC-heparin, MW 27 kDa (Cat#: X22-09-ZQ480) TRITC-heparin, MW 27 kDa (Cat#: X22-09-ZQ481) Biotin-heparin-FITC, MW 18 kDa (Cat#: X22-09-ZQ482) Chondroitin sulfate (dp4) (Cat#: X22-11-ZQ598) Dermatan sulfate (dp12) (Cat#: X22-11-ZQ611) Heparin disaccharide I-A (Cat#: X22-11-ZQ662) Chondroitine sulfate (Cat#: X23-04-XQ1118)
Carbohydrate Conjugates
GalNAcβ(1-4)GlcNAcβ-Sp3-Biotin (Cat#: X22-12-ZQ005) GalNAcβ(1-4)GlcNAcβ-Sp3-PAA-Biotin (Cat#: X22-12-ZQ006) GalNAcβ(1-4)GlcNAcβ-Sp3-PAA-FITC (Cat#: X22-12-ZQ007) GalNAcβ(1-4)GlcNAcβ-Sp3-PAA (Cat#: X22-12-ZQ008) Glcβ(1-4)GalNAcα-Sp3-Biotin (Cat#: X22-12-ZQ037) Glcβ(1-4)GalNAcα-Sp3-PAA-Biotin (Cat#: X22-12-ZQ038) Glcβ(1-4)GalNAcα-Sp3-PAA-FITC (Cat#: X22-12-ZQ039) Glcβ(1-4)GalNAcα-Sp3-PAA (Cat#: X22-12-ZQ040)
Glycolipids
GlcCer (d18:1/8:0) (Cat#: X23-11-ZQ101) GalCer (d18:1/16:0) (Cat#: X23-11-ZQ112) LacCer (d18:1/8:0) (Cat#: X23-11-ZQ118) Lc3Cer (d18:1/8:0) (Cat#: X23-11-ZQ131) Lc4Cer (d18:1/12:0) (Cat#: X23-11-ZQ146) Sialyl-Lc4Cer (d18:1/18:0) (Cat#: X23-11-ZQ162) Lewis a Cer (d18:1/16:0) (Cat#: X23-11-ZQ175) nLc4Cer (d18:1/18:0) (Cat#: X23-11-ZQ190)
Cyclodextrin
Methyl-γ-cyclodextrin (DS 12) (Cat#: X23-11-YM119) Carboxymethyl-ɑ-cyclodextrin sodium salt (Cat#: X23-11-B003) Carboxymethyl-γ-cyclodextrin sodium salt (Cat#: X23-11-B004) Succinyl-ɑ-cyclodextrin (Cat#: X23-11-B005) Succinyl-γ-cyclodextrin (Cat#: X23-11-B006) ɑ-Cyclodextrin sulfate sodium salt (Cat#: X23-11-B007) β-Cyclodextrin sulfate sodium salt (Cat#: X23-11-B008) γ-Cyclodextrin sulfate sodium salt (Cat#: X23-11-B009)
Dextran
Lysine-dextran, MW 4 kDa (Cat#: X22-09-ZQ273) Phenyl-dextran, MW 150 kDa (Cat#: X22-09-ZQ279) FITC-Q-dextran, MW 10 kDa (Cat#: X22-09-ZQ280) FITC-lysine-dextran, MW 10 kDa (Cat#: X22-09-ZQ283) TRITC-lysine-dextran, MW 10 kDa (Cat#: X22-09-ZQ287) FITC-dextran sulfate, MW 10 kDa (Cat#: X22-09-ZQ291) Dextran amine, MW 20 kDa (Cat#: X22-09-ZQ377) TRITC-dextran, MW 40 kDa (Cat#: X22-09-ZQ383) Biotin-dextran-FITC, MW 20 kDa (Cat#: X22-09-ZQ389)
Online Inquiry

About Us

CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.

Important Links

Contact Us

Copyright © CD BioGlyco. All rights reserved.
0